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1 |  INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a set of 
metabolic disorders characterized by increased hepatic 
lipid deposit, including non-alcoholic fatty liver (NAFL), 
non-alcoholic steatohepatitis (NASH), and liver cirrhosis. 
NAFLD has become one of the most common chronic liver 
diseases worldwide.1 Despite considerable efforts in the 
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Abstract
R-spondins (Rspos) are endogenous ligands of leucine-rich repeat-containing 
G-protein-coupled receptor 4 (LGR4). Rspos-LGR4 signaling plays important roles 
in embryogenesis, gastrointestinal homeostasis, and food intake. Here, we inves-
tigated the impacts of Rspos-LGR4 on hepatic cholesterol synthesis. Rspo1/3 and 
Lgr4 knockdown mice were used to investigate the impacts of Rspo1/3-LGR4 on 
hepatic cholesterol synthesis. AMPKα agonist, antagonist, and shRNA were used 
to explore the downstream targets of Rspos-LGR4 signaling. In our study, we re-
ported that LGR4, Rspo1, and Rspo3 were highly expressed in hepatocytes and their 
expressions were sensitive to energy states. Rspo1 and Rspo3 reversed OA-induced 
cholesterol synthesis, accompanying with increased the phosphorylation of AMPKα 
Thr172, reduced SREBP2 nuclear translocation, and Srebf2 mRNA expression. 
Conversely, hepatic LGR4 knockdown increased hepatic cholesterol synthesis and 
decreased the phosphorylation of AMPKα both in vitro and in vivo. Activation or in-
hibition of AMPKα significantly abolished the effects of LGR4 deficiency or Rspos, 
respectively, on cholesterol synthesis. Knockdown of AMPKα1 or/and AMPKα2 
repressed Rspos-induced inhibition on cholesterol synthesis. Our study indicates that 
Rspo1/Rspo3-LGR4 signaling in hepatocytes suppresses cholesterol synthesis via 
the AMPKα-SREBP2 pathway.
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study of NAFLD, its effective intervention remains limited. 
Researches have validated that the progression of NAFLD 
is accompanied by elevated cholesterol content in liver. In 
particular, the severity of NAFLD is positively correlated 
with increased hepatic synthesis of cholesterol.2 Lipidomic 
analysis of NAFLD also revealed a stepwise increment of 
hepatic free cholesterol in NASH compared with NAFL.3 
Consistently, clinical studies suggested that pharmaceuti-
cal interventions of cholesterol synthesis or absorption sig-
nificantly alleviate inflammation and fibrosis of NAFLD 
patients.4,5 All these findings indicated that the interven-
tion of cholesterol synthesis may also benefit the control of 
NAFLD, in addition to atherosclerosis.
The maintenance of hepatic cholesterol homeostasis de-
pends on the balance between cholesterol synthesis and 
removal. Previous studies revealed that both extracellular 
signals and intracellular molecules contribute to the dynamic 
control of hepatic cholesterol metabolism.6 One of the key 
intracellular modulators is a sterol regulatory element-bind-
ing protein 2 (SREBP2).6 Encoded by the Srebf2 gene, 
SREBP2 precursor is anchored on the endoplasmic reticu-
lum (ER) membrane and forms a heterodimeric complex with 
another ER membrane-bound protein—SREBP cleavage 
activation protein (SCAP).7 In response to sterol depletion, 
SREBP2-SCAP complex on ER membrane dissociates with 
ER-resident protein—insulin-induced gene (Insig), and trans-
ports from the ER membrane to Golgi where Golgi-localized 
Site-1 protease (S1P) and Site-2 protease (S2P) release the 
SREBP2 N terminus (SREBP2-N) from the membrane via 
proteolysis. Subsequently, SREBP2-N translocates into the 
nucleus to interact with the sterol regulatory element (SRE) 
of target genes to induce the transcription of relevant genes, 
leading to the increase of cholesterol synthesis.8
Leucine-rich repeat G-protein-coupled receptor 4 (LGR4), 
a member of subtype B of LGRs, is broadly expressed in 
cartilage, heart, hair follicle, and liver in mammals.9,10 Its 
endogenous ligands have been identified to be R-spondins 
(Rspos), which compose of Rspo1  ~  Rspo4. Rspos-LGR4 
signaling plays a pivotal role during embryogenesis as Lgr4 
null mice demonstrate severe intrauterine growth retardation 
and perinatal death.11 Additionally, Rspos-LGR4 signaling 
is involved in multiple physiological and pathophysiological 
processes, such as gastrointestinal homeostasis, tumorigene-
sis, and food intake.12,13 Of note, several recent studies have 
shed light on the probable functions of the Rspos-LGR4 axis 
in lipid metabolism. In skeletal muscle, Lgr4 homozygous 
mutation exhibited promoted lipid oxidation under fasting 
condition.14 Another study uncovers that Lgr4 deficient mice 
are resistant to diet- or genetic-induced obesity due to the pro-
motion of white-to-brown fat switch.15 Moreover, the expres-
sion pattern of Lgr4 in the liver exhibits a circadian rhythm. 
Lgr4 homozygous mutant mice display dampened circadian 
rhythms of plasma triglyceride.16 Whether Rspos-LGR4 
signaling alters cholesterol metabolism remains unexplored. 
The present study focuses on clarifying the impact of Rspos-
LGR4 signaling on hepatic cholesterol metabolism and its 
underlying mechanism.
2 |  MATERIALS AND METHODS
2.1 | Materials
Compound C, oleic acid (OA), palmitic acid (PA), and col-
lagenase IV were purchased from Sigma Aldrich (St. Louis, 
MO, USA). AICAR was purchased from MCE (NJ, USA). 
R-spondin 1 and R-spondin 3 were purchased from the R&D 
system (Minneapolis, MN). Rabbit anti-LGR4 was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Rabbit anti-AMPKα, rabbit anti-pAMPKα (Thr 172), and 
rabbit anti-β-catenin were purchased from Cell Signaling 
Technology (Beverly, MA). Rabbit anti-SREBP2, rabbit 
anti-AMPKα1, rabbit anti-AMPKα2 were purchased from 
Abcam (Cambridge, MA). Mouse anti-β-actin and mouse 
anti-lamin B1 were purchased from Proteintech (Chicago, 
USA). RNAtrip was purchased from Applygen (Beijing, 
China). The reverse transcription (RT) system was purchased 
from Invitrogen Inc (Carlsbad, CA). The nuclear protein ex-
traction kit was purchased from BestBio (Shanghai, China). 
Cholesterol assay kit and triglyceride assay kit were pur-
chased from Biosino Bio-technology & Science Inc (Beijing, 
China). Neofect DNA transfection reagent was purchased 
from Neofect Biotech (Beijing, China).
2.2 | Animals and treatments
Animals were housed in a thermostatic environment (24°C) 
with 12  h light and 12  h dark cycle, with access to food 
and water ad libitum. All experimental protocols were ap-
proved by the Animal Care and Use Committee of Peking 
University. Lgr4flox/flox mice were generated as described 
before.16 Albumin-Cre mice (C57BL/6J background) were 
purchased from Jackson Laboratory (Bar Harbor, ME). Four-
weeks-old Lgr4flox/flox mice were fed with normal chow diet 
(NCD) for 8 weeks or high-fat diet (HFD) for 12 weeks be-
fore injected with Ad-GFP or Ad-Cre (1010 pfu/mL) through 
the tail vein to knockdown hepatic Lgr4. After 4 d of injec-
tion, mice were sacrificed without fasting by intraperitoneal 
injection of pentobarbital sodium at 70 mg/kg body weight.
To generate the AL mice in which Lgr4 is specifically de-
leted in hepatocytes, Albumin-Cre mice were cross-bred with 
Lgr4flox/flox mice. Ablation of hepatic Lgr4 was confirmed 
by genotyping, quantitative RT-PCR, and Western blotting. 
Wild type (WT) and AL mice were fed with NCD for 8 weeks 
or HFD for 12 weeks before sacrifice.
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2.3 | Isolation and culture of primary 
hepatocytes
Mice were anesthetized by intraperitoneal injection of pento-
barbital sodium at 70 mg/kg body weight. 1000IU heparin 
was also administrated to prevent blood coagulation. After 
laparotomy, the portal vein was cannulated. The liver was 
quickly perfused with 20 mL of DHanks buffer (5 mL/min) 
pre-warmed in a 37°C water bath, followed by 30 mL of 0.03% 
pre-warmed collagenase IV (37°C) at a flow rate of 5 mL/
min. Subsequently, liver was carefully removed, and hepatic 
tissue was dispersed into the serum-free high glucose DMEM 
medium. Cell suspension was then filtered through 80  μm 
nylon mesh, centrifuged at 50 g/min, and washed twice using 
the serum-free high glucose DMEM medium. Hepatocytes 
dispersed in high glucose DMEM medium containing 10% 
fetal calf serum (FBS) were counted and seeded in a 6-well 
plate or 12-well plate at a concentration of 0.5-1 × 105 cells/
mL. Cells were cultured in a humid atmosphere (5% CO2) at 
37°C for 6 h to allow cell adhesion before changing to fresh 
high glucose DMEM medium supplemented with 10% FBS. 
Hepatocytes were then infected with Ad-GFP or Ad-Cre as 
indicated for 48 h. Where indicated, OA (125 μM) was added 
for 24 h, PA (300 μM) was added for 24 h, AICAR (0.5 mM) 
or compound C (40 μM) was supplied 1 h before harvest.
2.4 | Cell culture and shRNA transfection
AML12 cells (ATCC, Manassas, VA) were cultured in a humid 
atmosphere (5% CO2) with high glucose DMEM supplemented 
with 10% FBS at 37°C. Cells were seeded in a 12-well plate or 
6-well plate until 60%~80% confluent for transfection. The cell 
culture medium was replaced with 950 μL/well for the 12-well 
plate or 1.9 mL/well for the 6-well plate 2 h before transfection. 
The shRNA transfection mixture was prepared following the 
manufacturer's instructions. The mixture was then incubated 
for 18 min at 37°C and added into cells at the dose of 50 μL/
well for the 12-well plate or 100 μL/well for the 6-well plate. 
After 36  h of incubation, the culture medium was changed 
into high glucose DMEM supplemented with 10% FBS. Cells 
were then harvested or treated with OA (125 μM, 24 h), Rspo1 
(400 ng/mL, 6 h) or Rspo3 (200 ng/mL, 6 h). shRNA sequences 
are listed in Table S1.
2.5 | Gene expression analysis
RNA was extracted using RNAtrip and reverse-tran-
scribed into cDNAs using the reverse transcription system. 
Quantitative real time-PCR based on SYBER Green was 
performed using the Agilent AriaMx real-time PCR system. 
Primer sequences used in this research are listed in Table S2.
2.6 | Western blot analysis
Cells and liver tissue were homogenized in lysis buffer. 
The concentration of each protein sample was determined 
by the BCA protein quantitative kit (Applygen, Beijing, 
China). Protein samples were then subjected to SDS/PAGE 
running gel and transferred onto nitrocellulose (NC) mem-
brane. After incubated in 4% fat-free milk at room tem-
perature, membranes were incubated overnight at 4°C with 
primary antibodies. Fluorescent secondary antibodies were 
used to bind with primary antibodies and visualize the ex-
pression level of specific proteins. Odyssey infrared im-
aging systems (LI-COR Biosciences, Lincoln, NE, USA) 
were used to produce the graphical view of the fluores-
cence signals.
2.7 | Measurement of triglyceride and 
cholesterol contents
About 20  mg liver tissues were homogenized in 1  mL of 
chloroform/methanol mix (2:1) on ice and kept at 4°C over-
night to extract lipids into organic solution. Two hundred 
microliters of distilled water were added to the homogen-
ates. The mixture was vortexed and centrifuged for 10 min 
at 3000 rpm, 4°C. The under layer was collected using injec-
tors, followed by desiccating with nitrogen. The lyophilized 
powder of lipids was resolved in 5% Triton X-100 in PBS, 
and the supernatant was used for lipid detection. Triglyceride 
and cholesterol contents in liver, hepatocytes, and plasma 
were measured according to the manufacturer's instructions. 
Values were normalized to protein concentration or tissue 
weight.
2.8 | Oil red O staining
The oil red staining solution was prepared and filtered 
before using. Frozen sections of liver were prepared and 
rinsed in PBS for three times before fixed with 4% para-
formaldehyde for 10  min. After washing in PBS, slices 
were incubated in the oil red staining solution for 1  h at 
room temperature. Subsequently, sections were counter-
stained with hematoxylin for 30 s and rinsed using running 
water for 1 h. Finally, slides were mounted using 90% glyc-
erin for observation.
2.9 | Statistics
All data were expressed as mean ± SEM. Statistic difference 
was determined by two-way ANOVA and Student's t-test. 
P < .05 was considered significant.
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3 |  RESULTS
3.1 | Alteration of hepatic Rspo1/3 and 
LGR4 in response to energy status
To explore the functions of Rspos-LGR signaling in hepatic 
cholesterol metabolism, we firstly detected the expression of 
Rspos and LGRs subtypes in liver. As shown in Figure S1A, 
high levels of Rspo1 and Rspo3 were detected in liver, es-
pecially Rspo3. In contrast, levels of Rspo2 and Rspo4 were 
negligible. The expression of LGR4 was prominently higher 
than its two homologues—LGR5 and LGR6 (Figure S1A). 
Since liver is composed of multiple cell types, such as hepat-
ocytes, Kupffer cells, and hepatic stellate cells, we further de-
termined the expression of Rspos and LGR4 in different cell 
types. As shown in Figure S1B, both Rspo1 and Rspo3 are 
predominantly expressed in hepatocytes rather than Kupffer 
cells. Similarly, apart from hepatocytes, LGR4 was negligi-
ble in other cells such as Kupffer cells, macrophage cell line 
Raw264.7, and stellate cell line LX-2 (Figure S1B,C).
We next examined the alteration of hepatic Rspo1/Rspo3 
and LGR4 in response to various energy statuses. Relative 
to the animals fed with normal chow diet (NCD), mice fed 
high-fat diet (HFD) showed decreased expression of Rspo1 in 
liver, while the expression levels of Rspo3 and Lgr4 remained 
unaltered (Figure S1D). Consistent with the in vivo results, 
treating primary hepatocytes with oleic acid (OA) to mimic 
the in vivo positive energy balance also down-regulated 
Rspo1, while Rspo3 and Lgr4 were unaffected (Figure S1E). 
Moreover, fasting significantly up-regulated Rspo1 in liver 
relative to the control fed group (Figure S1F). This change 
was reversed upon re-feeding (Figure S1F). Rspo3 and Lgr4 
showed similar but less significant changes relative to Rspo1 
(Figure  S1F). These results indicate that Rspos-LGR4 sig-
naling may modulate metabolic homeostasis under different 
energy statuses.
3.2 | Inhibition of hepatic cholesterol 
synthesis by Rspo1/3
To explore the effects of Rspo1/3-LGR4 signaling on hepatic 
cholesterol metabolism, we treated AML12 hepatocytes with 
Rspo1 or Rspo3. The optimal doses of Rspo1 or Rspo3 were 
determined by detecting their effects on the expression of 
β-catenin nuclear translocation and β-catenin target genes, 
a well-characterized effect for Rspos-LGR4 signaling.17 As 
shown in Figure S2A,B, 200 ng/mL of Rspo3, and 400 ng/
mL of Rspo1 were proven to be effective. Both effective 
doses of Rspo1 and Rspo3 could reverse OA-induced el-
evation of cholesterol content (Figure 1A). However, some 
previous reports suggested that OA inhibits cholesterol syn-
thesis in C6 glioma cells.18 Therefore, we also used PA to 
induce the accumulation of cholesterol and found consistent 
results upon Rspo1 or Rspo3 stimulation (Figure S2C). Later 
on, we used OA to increase cholesterol content in hepato-
cytes. OA increased the expression of Srebf2—a transcrip-
tion factor crucial for cholesterol synthesis, as well as its 
downstream target genes, that is, Ldlr, Hmgcs1, and Hmgcr. 
Importantly, Rspo1 treatment blocked the effects of OA on 
these genes (Figure 1B). Further, Rspo1 decreased SREBP2 
nuclear translocation (Figure 1D). The effects of Rspo3 were 
similar to Rspo1 (Figure 1C,E). These results indicate that 
both Rspo1 and Rspo3 could suppress hepatic cholesterol 
synthesis via restraining SREBP2 transcription and nuclear 
translocation.
3.3 | Increment of cholesterol synthesis 
upon the deficiency of hepatic LGR4
To further validate the effects of Rspos-LGR4 signaling on 
hepatic cholesterol metabolism, we constructed Lgr4flox/flox 
mice and knocked down hepatic LGR4 through tail vein 
injection of Cre adenovirus (Ad-Cre). After 4 d of Ad-Cre 
injection, the expression of Lgr4 in liver was significantly re-
strained compared with the control group injected with GFP 
adenovirus (Ad-GFP) (Figure S3A). We also confirmed both 
NCD and HFD Lgr4flox/flox mice displayed decreased hepatic 
LGR4 protein expression after Ad-Cre injection (Figure S3B). 
Four-weeks-old Lgr4flox/flox mice were fed with NCD for 
8 weeks, then divided into two groups randomly and injected 
with Ad-GFP or Ad-Cre. Body weight and tissue weights of 
hepatic Lgr4 knockdown (Lgr4LKO) mice were unchanged 
relative to their littermate (Figure S3C). Histochemistry and 
Oil red O staining also showed no significant differences 
between two groups (Figure  S3E,F). However, the hepatic 
cholesterol content of Lgr4LKO mice was 1.5-fold of Lgr4flox/
flox mice (Figure 2A). No significant change in serum choles-
terol, serum, and hepatic triglyceride was observed between 
the two groups (Figure 2A). Srebf2 was induced in Lgr4LKO 
mice (Figure 2B). This change was associated with a signifi-
cant increase of SREBP2 nuclear translocation (Figure 2E). 
Consistently, Srebf2 target genes Ldlr, Hmgcs1, and Hmgcr 
were significantly up-regulated (Figure 2B).
We next examined the impacts of hepatic LGR4 de-
letion on cholesterol synthesis under HFD condition. 
Four-weeks-old Lgr4flox/flox mice were fed with HFD for 
12 weeks, followed by Ad-Cre or Ad-GFP injection. After 
4 d of injection, no significant difference was observed be-
tween Lgr4flox/flox and Lgr4LKO mice with regard to body 
weight and tissue weights (Figure  S3D). Histochemistry 
and Oil red O staining showed increased lipid in the 
liver of Lgr4LKO mice compared with Lgr4flox/flox mice 
(Figure S3G,H). Consistently, hepatic cholesterol and tri-
glyceride contents of Lgr4LKO mice increased by 2-folds 
14950 |   LIU et aL.
relative to Lgr4flox/flox mice, while serum cholesterol and 
triglyceride levels remained unaltered (Figure 2C). Under 
HFD condition, Lgr4 deficiency resulted in an increase of 
Srebf2 and its target genes, including Ldlr, Hmgcs1, and 
Hmgcr (Figure 2D). SREBP2 nuclear translocation in the 
liver of HFD Lgr4LKO mice was enhanced (Figure  2F). 
Thus, transient ablation of hepatic Lgr4 in mice fed either 
NCD or HFD enhanced the expression and nuclear translo-
cation of Srebf2 as well as its downstream targets, leading 
to a subsequent increase of cholesterol synthesis.
We next examined the effect of stable deficiency of Lgr4 
on hepatic cholesterol metabolism using the hepatic specific 
Lgr4 knockout mice (AL). Lgr4flox/flox littermates (WT) were 
used as control. As shown in Figure S4A, body weight and 
most of the tissue weight were comparable between WT and 
AL mice fed NCD. Liver weight of AL mice slightly reduced 
accompanied by decreased expression of LGR4 protein in 
liver (Figure  S4A,C). Histochemistry staining showed he-
patocyte vacuolization of AL mice (Figure S4D). However, 
Oil red O staining was comparable between two groups 
(Figure  S4E). Hepatic cholesterol content in AL mice ele-
vated relative to WT mice, whereas no significant increase in 
hepatic triglyceride levels was observed (Figure 3A). Serum 
levels of cholesterol and triglyceride also increased com-
pared with the littermates (Figure 3A). Hepatic mRNA lev-
els of Lgr4 decreased as expected, whereas levels of Srebf2, 
Hmgcs1, and Hmgcr significantly increased in AL mice 
(Figure 3B). Consistent with the change at the mRNA level, 
hepatic Lgr4 ablation enhanced the translocation of SREBP2 
into nuclei (Figure 3E). Similar results were observed for AL 
mice fed HFD. After 12  weeks of HFD, liver weight, and 
hepatic LGR4 expression of AL mice decreased, while body 
F I G U R E  1  Inhibition of hepatic cholesterol synthesis by Rspo1/3. A, Cholesterol content in AML12 cells under different treatments. AML12 
cells were treated with OA (125 μM) for 24 h, followed by 6 h incubation with Rspo1 or Rspo3. Cholesterol contents were determined using 
assay kits. n = 4. B, Rspo1 repressed expression of genes related to cholesterol uptake and synthesis upon OA treatment. Hepatic mRNAs were 
extracted and analyzed by quantitative RT-PCR. n = 6. C, Rspo3 repressed expression of genes related to cholesterol uptake and synthesis upon 
OA treatment. Hepatic mRNAs were extracted and analyzed by quantitative RT-PCR. n = 6. D, Rspo1 reversed SREBP2 nuclear translocation 
induced by OA. Western blotting was performed to detect the protein level of SREBP2 in the nucleus and cytoplasm. The relative expression level 
of SREBP2 was calculated using Image J software. Shown is the representative of at least three repeat experiments. E, Rspo3 reversed SREBP2 
nuclear translocation induced by OA. Western blotting was performed to detect the protein level of SREBP2 in the nucleus and cytoplasm. The 
relative expression level of SREBP2 was calculated using Image J software. Shown is the representative of at least three repeat experiments. Data 
are represented as mean ± SEM. *P < .05
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weights of AL and WT mice were identical (Figure S4B,C). 
Although the histochemistry staining showed no significant 
changes, there was an increased the accumulation of perivas-
cular lipid in the liver of AL mice (Figure S4F,G). In com-
parison to WT mice, AL mice demonstrated a significant 
increase in hepatic and serum levels of cholesterol and tri-
glyceride (Figure 3C). Deficiency of Lgr4 boosted the tran-
scription of Srebf2 (Figure  3D) and its subsequent nuclear 
translocation (Figure 3F) in AL mice fed HFD. Associated 
with the change in SREBP2, its downstream target genes sig-
nificantly up-regulated, such as Pcsk9, Hmgcs1, and Hmgcr 
(Figure 3D).
In summary, either transient or stable ablation of he-
patic LGR4 in mice fed NCD or HFD promotes cholesterol 
synthesis, SREBP2 transcription, and nuclear translocation, 
expression of genes relevant to cholesterol synthesis.
3.4 | Cell-autonomous effect of hepatic 
LGR4 deficiency
To verify that the effects of LGR4 deficiency on hepatic 
cholesterol synthesis are cell-autonomous, we isolated 
primary hepatocytes from Lgr4flox/flox mice and knocked 
down Lgr4 through Ad-Cre administration. Primary hepat-
ocytes of Lgr4flox/flox mice were treated with Ad-GFP or 
Ad-Cre for indicated times. After 48 h of treatment, LGR4 
mRNA and protein were both effectively suppressed 
F I G U R E  2  Increment of cholesterol synthesis upon hepatic LGR4 knockdown using Ad-Cre. A, NCD Lgr4LKO mice displayed increased 
hepatic cholesterol content. Hepatic and serum cholesterol, triglyceride contents were measured by assay kits. n = 6. B, Upregulation of genes 
related to cholesterol uptake and synthesis in the liver of NCD Lgr4LKO mice. Hepatic mRNAs were extracted and analyzed by quantitative 
RT-PCR. n = 6. C, Increased hepatic cholesterol and triglyceride contents in HFD Lgr4LKO mice. Hepatic and serum triglyceride and cholesterol 
contents were measured by assay kits. n = 6. D, Upregulation of genes related to cholesterol uptake and synthesis in the liver of HFD Lgr4LKO 
mice. Hepatic mRNAs were extracted and analyzed by quantitative RT-PCR. n = 6. E, Increased hepatic SREBP2 nuclear translocation in NCD 
Lgr4LKO mice. Western blotting was performed to detect the protein level of SREBP2 in the nucleus and cytoplasm. The relative expression level 
of SREBP2 was calculated using Image J software. Shown is the representative of at least three repeat experiments. F, Increased hepatic SREBP2 
nuclear translocation in HFD Lgr4LKO mice. Western blotting was performed to detect the protein level of SREBP2 in the nucleus and cytoplasm. 
The relative expression level of SREBP2 was calculated using Image J software. Shown is the representative of at least three repeat experiments. 
Data are represented as mean ± SEM. *P < .05
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(Figure  4A,B). LGR4 deficiency promoted cholesterol 
deposition in hepatocytes under conditions treated with or 
without OA (Figure 4C). An increase of triglyceride con-
tent in hepatocytes was only observed after OA stimulation 
in LGR4 deficient hepatocytes (Figure 4C). These changes 
were associated with an increase of genes relevant to cho-
lesterol metabolism such as Pcsk9, Ldlr, Srebf2, Hmgcs1, 
and Hmgcr (Figure  4D). LGR4 deficient hepatocytes 
showed a remarkable increase of SREBP2 translocation 
into nuclei (Figure 4E).
3.5 | AMPKα dependent mechanism
Adenosine monophosphate (AMP)-activated protein kinase 
(AMPK) is one of the pivotal energy-sensing molecules 
expressed in almost all eukaryotic cells. Numerous studies 
have confirmed that AMPK is critical for cellular energy 
metabolism such as GLUT4 membrane translocation, fatty 
acid β oxidation, mitochondrial biogenesis, and autophagy.19 
Studies from ours and others have demonstrated that AMPK 
directly phosphorylates SREBP2 precursor, leading to the 
F I G U R E  3  Hepatic stable deficiency of Lgr4 promoted cholesterol synthesis. Four-weeks-old hepatic specific LGR4 deficient mice (AL 
mice) and their Lgr4flox/flox littermate (WT mice) were fed with normal chow diet for 8 weeks or high-fat diet for 12 weeks before sacrifice. A, 
Elevated hepatic cholesterol and serum cholesterol, triglyceride level of NCD AL mice compared with WT mice. Hepatic and serum cholesterol, 
triglyceride contents were measured by assay kits. n = 6. B, Hepatic specific Lgr4 knockdown increased cholesterol uptake and synthesis of 
NCD mice. Hepatic mRNAs were extracted and analyzed by quantitative RT-PCR. n = 6. C, Elevated hepatic and serum cholesterol, triglyceride 
level of HFD AL mice compared with WT mice. Hepatic and serum cholesterol, triglyceride contents were measured by assay kits. n = 6. D, 
Hepatic specific LGR4 knockdown increased cholesterol uptake and synthesis of HFD mice. Hepatic mRNAs were extracted and analyzed by 
quantitative RT-PCR. n = 6. E, Hepatic specific Lgr4 knockdown increases the nuclear translocation of SREBP2 of NCD mice. Western blotting 
was performed to detect the protein level of SREBP2 in the nucleus and cytoplasm. The relative expression level of SREBP2 was calculated using 
Image J software. Shown is the representative of at least three repeat experiments. F, Hepatic specific LGR4 knockdown increases the expression 
of SREBP2 of HFD mice. Western blotting was performed to detect the protein level of SREBP2 in the nucleus and cytoplasm. The relative 
expression level of SREBP2 was calculated using Image J software. Shown is the representative of at least three repeat experiments. Data are 
represented as mean ± SEM. *P < .05
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reduction of SREBP2 nuclear translocation.6,20,21 We thus 
examined the effects of Rspo1/3-LGR4 signaling on AMPK. 
As shown in Figure 5A, both Rspo1 and Rspo3 stimulation 
potentiated the phosphorylation of Thr172 site of AMPKα 
in AML12 cells, indicating AMPK activation. Compound 
C is commonly used as an AMPK antagonist. As presented 
in Figure S5A, incubation of AML12 cells with compound 
C for 1 h dose-dependently reduced the phosphorylation of 
AMPKα Thr172. Rspo1 and Rspo3 significantly attenuated 
OA-induced elevation of the cholesterol content in AML12 
cells (Figure  5B). This effect was blunted by compound 
C (Figure  5B). Compound C significantly attenuated the 
Rspo1-induced activation of AMPKα and subsequent sup-
pression of cholesterol metabolism relevant genes includ-
ing Srebf2, Ldlr, Hmgcs1, and Hmgcr, as well as the nuclear 
translocation of SREBP2 in hepatocytes treated with OA 
(Figure 5C,D). Similarly, compound C abolished the effects 
of Rspo3 on AMPKα, cholesterol metabolism relevant genes, 
and the SREBP2 nuclear translocation (Figure 5E,F).
In Lgr4flox/flox mice fed NCD and HFD, transient knock-
down of hepatic LGR4 using Ad-Cre resulted in reduced 
activation of AMPKα (Figure 6A). Similarly, the phosphor-
ylation of AMPKα in liver with stable deletion of LGR4 
(AL mice) significantly declined compared with WT mice 
(Figure  6A). In vitro, knockdown LGR4 in Lgr4flox/flox he-
patocytes using Ad-Cre suppressed activation of AMPKα as 
well (Figure 6B). We then tested if AMPKα agonist AICAR 
could reverse the changes driven by LGR4 depletion. In 
AML12 cells, AICAR dose-dependently potentiated AMPKα 
phosphorylation at the Thr172 site (Figure S5B). Activation 
of AMPKα by AICAR significantly attenuated the increase 
of hepatic cholesterol content in LGR4 deficient hepatocytes 
treated with or without OA (Figure 6C). Consistently, AICAR 
abolished the up-regulation of Srebf2 and its target genes in-
cluding Ldlr, Hmgcs1, and Hmgcr induced by LGR4 deletion 
(Figure 6D). Additionally, AICAR treatment was sufficient 
to block the SREBP2 nuclear translocation induced by LGR4 
ablation (Figure 6E).
F I G U R E  4  Cell-autonomous effect of hepatic LGR4 deficiency. A, Ad-Cre-induced Lgr4 knockdown in Lgr4flox/flox primary hepatocytes. 
Primary hepatocytes from Lgr4flox/flox mice were isolated and infected with Ad-GFP or Ad-Cre (108 pfu/mL) for the indicated time. mRNAs were 
extracted and analyzed by quantitative RT-PCR. n = 6. B, Ad-Cre suppressed expression of LGR4 protein in Lgr4flox/flox primary hepatocytes. 
Western blotting was performed to detect the protein level of LGR4. The relative expression level of LGR4 was calculated using Image J software. 
Shown is the representative of at least three repeat experiments. C, LGR4 deficiency of hepatocytes increases cholesterol content. Lgr4flox/flox 
primary hepatocytes were incubated with Ad-Cre or Ad-GFP for 48 h, followed by 24 h of OA or DMSO treatment. Cholesterol and triglyceride 
content in hepatocytes were then determined after different treatments by assay kits. n = 6. D, LGR4 deficiency of hepatocytes increases cholesterol 
uptake and synthesis. After indicated treatments, mRNA was extracted from primary hepatocytes and analyzed by quantitative RT-PCR. n = 6. 
E, LGR4 deficiency of hepatocytes increases the nuclear translocation of SREBP2. After indicated treatments, western blotting was performed to 
detect the protein level of SREBP2 in the nucleus and cytoplasm. The relative expression level of SREBP2 was calculated using Image J software. 
Shown is the representative of at least three repeat experiments. Data are represented as mean ± SEM. *P < .05
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Two isoforms of AMPKα have been identified to date, 
namely, AMPKα1 and AMPKα2.22 To explore the isoform 
mediating the downstream effects of Rspo1/3-LGR4 signal-
ing, we constructed shRNA specifically interfering AMPKα1 
or AMPKα2. AML12 cells transfected with AMPKα1 
shRNA for 36 h demonstrated a significant reduction in the 
levels of AMPKα1, while AMPKα2 levels were unaffected 
(Figure  7A). Remarkably, AMPKα1 deficiency abrogated 
the inhibitory effects of Rspo1 on cholesterol synthesis 
(Figure  7A), mRNA levels of Srebf2, Ldlr, Hmgcs1, and 
Hmgcr (Figure 7B), as well as the nuclear translocation of 
SREBP2 (Figure  7C). AMPKα1 deficiency reduced the 
Rspo1-induced upregulation of AMPKα phosphorylation 
(Figure  7C). Similar results were also found upon Rspo3 
stimulation (Figure S6A-C).
As shown in Figure  7D, AML12 cells transfected with 
AMPKα2 shRNA for 36 h significantly reduced the expres-
sion level of AMPKα2 without affecting AMPKα1. Much 
F I G U R E  5  Rspo1/3 inhibits cholesterol synthesis through activating AMPKα. A, Rspo1/3 promoted activation of AMPKα. AML12 cells 
were treated with OA for 24 h and then incubated with Rspo1/Rspo3 for 6 h. Western blotting was performed to detect protein levels. The 
relative expression levels of proteins were calculated using Image J software. Shown is the representative of at least three repeat experiments. B, 
Compound C diminished the inhibitory effects of Rspo1/3 on cholesterol accumulation. AML12 cells were treated with OA for 24 h, followed by 
Rspo1/Rspo3 for 6 h. Afterward, AML12 cells were incubated with compound C (40 μM) for 1 h. Cholesterol contents in hepatocytes were then 
determined by assay kits. n = 4. C, Compound C diminishes the inhibitory effects of Rspo1 on cholesterol uptake and synthesis. After indicated 
treatments, mRNA was extracted from hepatocytes and analyzed by quantitative RT-PCR. n = 6. D, Compound C diminishes the inhibitory effects 
of Rspo1 on the nuclear translocation of SREBP2. Western blotting was performed to detect protein levels. The relative expression levels of 
proteins were calculated using Image J software. Shown is the representative of at least three repeat experiments. E, Compound C diminishes the 
inhibitory effects of Rspo3 on cholesterol uptake and synthesis. After indicated treatments, mRNA was extracted from hepatocytes and analyzed 
by quantitative RT-PCR. n = 6. F, Compound C diminishes the inhibitory effects of Rspo3 on the nuclear translocation of SREBP2. Western 
blotting was performed to detect protein levels. The relative expression levels of proteins were calculated using Image J software. Shown is the 
representative of at least three repeat experiments. Data are represented as mean ± SEM. *P < .05
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alike AMPKα1 knockdown, AMPKα2 deletion also reversed 
the decrease of cholesterol level (Figure 7D), mRNA levels of 
cholesterol metabolism relevant genes such as Srebf2, Ldlr, 
Hmgcs1, and Hmgcr (Figure 7E), and nuclear translocation 
of SREBP2 (Figure 7F) in hepatocytes treated with Rspo1. 
The silence of the AMPKα2 gene significantly attenuated 
the increase of AMPKα phosphorylation induced by Rspo1 
(Figure  7F). Much like Rspo1, AMPKα2 knockdown he-
patocytes displayed similar results under Rspo3 treatment 
(Figure S6D-F).
Hepatocytes with double-knockdown of AMPKα1 and 
AMPKα2 were resistant to Rspo1 or Rspo3 induced the 
F I G U R E  6  LGR4 ablation promotes cholesterol synthesis through inhibiting AMPKα. A, Transient and stable hepatic LGR4 knockdown 
repressed AMPKα activation. Western blotting was performed to detect the level of AMPKα phosphorylation in liver. The relative expression 
levels of proteins were calculated using Image J software. Shown is the representative of at least three repeat experiments. B, LGR4 depletion 
suppressed AMPKα activation in hepatocytes. Western blotting was performed to detect the level of AMPKα phosphorylation in Lgr4flox/flox 
primary hepatocytes after indicated treatment. The relative expression levels of proteins were calculated using Image J software. Shown is the 
representative of at least three repeat experiments. C, AICAR reversed LGR4 knockdown-induced cholesterol accumulation. Lgr4flox/flox primary 
hepatocytes were incubated with Ad-Cre or Ad-GFP for 48 h, followed by AICAR (0.5 mM) treatment for 1 h. Cholesterol contents in hepatocytes 
of different treatments were then determined by assay kits. n = 4. D, AICAR reversed LGR4 knockdown-induced cholesterol uptake and synthesis. 
After indicated treatments, mRNA was extracted from hepatocytes and analyzed by quantitative RT-PCR. E, AICAR reversed LGR4 knockdown-
induced nuclear translocation of SREBP2. Western blotting was performed to detect protein levels. The relative expression levels of proteins were 
calculated using Image J software. Shown is the representative of at least three repeat experiments. Data are represented as mean ± SEM. *P < .05
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decline of cholesterol level (Figure  S7A,B). The effects of 
Rspo1 and Rspo3 on cholesterol metabolism relevant genes 
such as Srebf2, Ldlr, Hmgcs1, Hmgcr were significantly 
blunted in hepatocytes with ablation of both AMPKα1 and 
AMPKα2 (Figure  S7C,D). Likewise, the inhibitory effects 
of Rspo1 and Rspo3 on SREBP2 nuclear translocation were 
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apparently abolished in hepatocytes with deficiency of both 
AMPKα1 and AMPKα2 (Figure S7E,F).
4 |  DISCUSSION
Rspos-LGR4 signaling has been demonstrated to be critical 
for embryogenesis and maintenance of stem cell functions. 
The present study reveals a pivotal role for this signaling 
pathway in the cholesterol homeostasis. The highlights of 
our study are as follows: (a) Rspo1/3 inhibits hepatic choles-
terol synthesis, while LGR4 deficiency increases cholesterol 
contents in hepatocytes; (b) Rspo1/3 activates AMPKα, and 
subsequently blocks the transcriptional activation of Srebf2 
and the SREBP2 nuclear translocation, leading to the sup-
pression of its target genes involved in cholesterol synthesis, 
while the deletion of hepatic LGR4 induced opposite effects; 
(c) Both pharmacological or genetic intervention of AMPKα 
reverse the inhibitory effects of Rspo1 and Rspo3 on he-
patic cholesterol synthesis. Our study thus demonstrates that 
Rspo1/3-LGR4 signaling inhibits hepatic cholesterol synthe-
sis through a mechanism dependent on the AMPK-SREBP2 
pathway (Figure 8).
Being mainly expressed in the stem cells, LGR4 is 
critical for the maintenance of stem cells and thus for the 
embryonic development.11 Our finding extends the physi-
ological function of LGR4 to the cholesterol homeostasis. 
Conflicting results have been reported on the metabolic 
F I G U R E  8  Schematic diagram showing the mechanism by which Rspo1/Rspo3- LGR4 signaling inhibits hepatic cholesterol synthesis. In 
hepatocytes, Rspo1/3 bind to their receptor LGR4 to promote phosphorylate of AMPKα. The activated AMPKα will further restrain the expression 
and nuclear translocation of SREBP2; therefore, downregulate transcription of genes related to cholesterol uptake and synthesis, including Ldlr, 
Hmgcs1, and Hmgcr
F I G U R E  7  AMPKα1/2 knockdown abolished the inhibitory effects of Rspo1-LGR4 signaling on hepatic cholesterol synthesis. A, AMPKα1 
knockdown diminishes the inhibitory effects of Rspo1 on cholesterol accumulation. AML12 cells were transfected with AMPKα1 shRNA for 36 h. 
mRNA was extracted from hepatocytes and analyzed by quantitative RT-PCR. n = 6. *P < .05 vs shCtrl. After the transfection, cells were treated 
by OA for 24 h and stimulated by Rspo1 for 6 h. Cholesterol contents in hepatocytes after different treatments were determined by assay kits. n = 4. 
B, AMPKα1 knockdown reversed Rspo1-induced downregulation of genes related to cholesterol uptake and synthesis. After indicated treatments, 
mRNA was extracted from hepatocytes and analyzed by quantitative RT-PCR. C, AMPKα1 knockdown diminishes the inhibitory effects of 
Rspo1 on the nuclear translocation of SREBP2. Western blotting was performed to detect protein levels. The relative expression levels of proteins 
were calculated using Image J software. Shown is the representative of at least three repeat experiments. D, AMPKα2 knockdown diminishes the 
inhibitory effects of Rspo1 on cholesterol accumulation. AML12 cells were transfected with AMPKα2 shRNA for 36 h, mRNA was extracted 
from hepatocytes and analyzed by quantitative RT-PCR. n = 6. *P < .05 vs shCtrl. After the transfection, cells were treated by OA for 24 h and 
stimulated by Rspo1 for 6 h. Cholesterol contents in hepatocytes after different treatments were determined by assay kits. n = 4. E, AMPKα2 
knockdown reversed Rspo1-induced downregulation of genes related to cholesterol uptake and synthesis. After indicated treatments, mRNA was 
extracted from hepatocytes and analyzed by quantitative RT-PCR. n = 6. F, AMPKα2 knockdown diminishes the inhibitory effects of Rspo1 on 
the nuclear translocation of SREBP2. Western blotting was performed to detect protein levels. The relative expression levels of proteins were 
calculated using Image J software. Shown is the representative of at least three repeat experiments. Data are represented as mean ± SEM. *P < .05
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function of LGR4. In the hypothalamus, activation of LGR4 
by R-spondin 1 or 3 inhibits food intake.23 In contrast, mice 
with global ablation of LGR4 show decrement in adiposity 
and resistance to dietary and leptin mutant-induced obe-
sity, due to enhanced browning of white adipose tissues.14 
Consistently, human genetic analysis has identified the 
gain-of-function variant of LGR4, LGR4 A750T variant, as 
a genetic determinant of central obesity.24 All these studies 
suggest that LGR4 may either function as an anorexic sig-
nal through the central hypothalamus or as a stimulator for 
energy expenditure through peripheral adipose tissues to 
promote negative or positive energy balance, respectively. 
Thus, conditional manipulation of LGR4 in distinct cells 
such as hypothalamic neurons, adipocytes, hepatocytes, 
and islet cells is a critical precondition to dissect the differ-
ential action of this molecule on energy homeostasis. Using 
the in vivo and in vitro approach to specifically manipulate 
the expression of the LGR4 gene in hepatocytes, we reveal 
an additional physiological function for LGR4 in choles-
terol metabolism. Activation of LGR4 in hepatocytes by 
R-spondin 1 or 3 attenuated cholesterol synthesis, whereas 
deficiency of LGR4 in hepatocytes significantly increased 
the synthesis of cholesterol both in mice and in cultured 
hepatocytes. The reduction of hepatic cholesterol upon the 
activation of LGR4 may occur through the attenuation of 
cholesterol synthesis. Our study thus establishes Rspo1/3-
LGR4 signaling as a novel endogenous system contributing 
to the cholesterol homeostasis. Targeting the Rspos-LGR4 
signaling in hepatocytes may provide an alternative strat-
egy for the intervention of cholesterol dysfunction includ-
ing hypercholesterolemia.
The intracellular signaling pathway mediating the physi-
ological function of Rspos-LGR4 remains largely unknown. 
Previous study has suggested that Rspos-LGR4 functions 
to potentiate Wnt/β-catenin signaling.17 We have identified 
AMPKα-SREBP2 as the downstream mediators of Rspo1/3-
LGR4 signaling in the control of hepatic cholesterol syn-
thesis. Both pharmacological and genetic intervention of 
AMPKα reversed the decrement of SREBP2 nuclear trans-
location induced by Rspo1/3 and suppressed cholesterol 
synthesis. Conversely, AMPKα agonist abolished the en-
hancement of cholesterol synthesis in the context of LGR4 
ablation. Furthermore, both isoforms of AMPKα are required 
for the suppression of hepatic cholesterol synthesis induced 
by Rspo1/3-LGR4 signaling.
How Rspo1/3-LGR4 signaling activates AMPKα remains 
unclear. Having been extensively verified, the major function 
of the Rspos-LGR4 pathway is to potentiate Wnt/β-catenin 
signaling. Accordingly, we assume that the Wnt/β-catenin 
axis may be responsible for the ectopic activation of AMPKα. 
Glycogen synthase kinase 3β (GSK3β) negatively regulates 
Wnt/β-catenin signaling through accelerating the degrada-
tion of β-catenin. Previous studies have demonstrated that 
GSK3β acts as a potent inhibitor of AMPK activation.25,26 
Further study is required to determine whether GSK3β is in-
volved in Rspos-LGR4 stimulated AMPK phosphorylation in 
hepatocytes.
In summary, our study demonstrates that in liver, Rspos-
LGR4 signaling functions as a crucial endogenous path-
way to inhibit cholesterol synthesis through suppressing 
SREBP2 as well as its downstream targets. This function of 
the Rspos-LGR4 axis is mediated by AMPKα. Considering 
that the elevation of cholesterol in liver is critical for the 
progression from NAFL to NASH, our finding suggests 
that the Rspos-LGR4 axis may provide novel therapeutic 
targets for NAFLD.
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